Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant mannan-binding lectin (MBL) for therapy.

J C Jensenius1, P H Jensen, K McGuire

  • 1Department of Medical Microbiology and Immunology, University of Aarhus, Denmark. j.c.jensenius@immunology.au.dk

Biochemical Society Transactions
|July 31, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lectin complement pathway proteins in healthy individuals.

Clinical and experimental immunology·2016
Same author

Oligomerization of Mannan-binding Lectin Dictates Binding Properties and Complement Activation.

Scandinavian journal of immunology·2016
Same author

Collectin liver 1 and collectin kidney 1 and other complement-associated pattern recognition molecules in systemic lupus erythematosus.

Clinical and experimental immunology·2015
Same author

Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2014
Same author

DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease.

Cell death & disease·2014
Same author

Selective renal vasoconstriction, exaggerated natriuresis and excretion rates of exosomic proteins in essential hypertension.

Acta physiologica (Oxford, England)·2014
Same journal

TDP-43 proteinopathy as a biomarker and therapeutic target in amyotrophic lateral sclerosis.

Biochemical Society transactions·2026
Same journal

Advancing the monitoring of organelle contact sites in vitro and in vivo.

Biochemical Society transactions·2026
Same journal

Mechanisms influencing transient cytoplasmic protein targeting to intracellular lipid droplets.

Biochemical Society transactions·2026
Same journal

Replication associated nuclear DNA mismatch repair across kingdoms.

Biochemical Society transactions·2026
Same journal

Phosphatases of regenerating liver downregulate PTEN to promote tumorigenesis.

Biochemical Society transactions·2026
Same journal

Implications of Rho GTPase signaling in cancer immunotherapy.

Biochemical Society transactions·2026
See all related articles

Recombinant mannan-binding lectin (MBL), produced by a human cell line, demonstrates biological activity identical to plasma-derived MBL. This advancement paves the way for clinical trials in MBL-deficient individuals to combat infections.

Area of Science:

  • Immunology
  • Biotechnology
  • Protein Therapeutics

Background:

  • Mannan-binding lectin (MBL) is crucial for innate immunity, mediating pathogen recognition and clearance via complement activation.
  • Genetic deficiencies in MBL correlate with heightened susceptibility to various infections.
  • Previous trials using plasma-derived MBL showed safety but faced production challenges.

Purpose of the Study:

  • To develop a safe and scalable method for producing biologically active MBL.
  • To establish recombinant MBL (rMBL) as a viable therapeutic alternative to plasma-derived MBL.
  • To prepare for upcoming clinical trials of rMBL.

Main Methods:

  • A human cell line was transfected to produce MBL.
  • The biological activity of the produced rMBL was assessed.

Related Experiment Videos

  • Mass spectrometry (MS) was used to compare rMBL with plasma-derived MBL.
  • Production was scaled up for clinical use.

    • Main Results:

    • The transfected cell line successfully produced MBL with biological activity comparable to plasma-derived MBL.
    • Mass spectrometry confirmed an essentially identical profile for rMBL and native MBL.
    • Production scale-up was achieved, enabling further clinical development.

    Conclusions:

    • Recombinant MBL production using a transfected human cell line is feasible and yields a product with equivalent biological function.
    • This method offers a scalable and potentially safer alternative for MBL replacement therapy.
    • The successful scale-up and product characterization support the initiation of clinical trials for MBL-deficient individuals.